Cargando…

Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis

Detalles Bibliográficos
Autores principales:	Singh, Awadhesh Kumar, Singh, Ritu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240079/ https://www.ncbi.nlm.nih.gov/pubmed/28217490 http://dx.doi.org/10.4103/2230-8210.196026

Ejemplares similares

Triglyceride and cardiovascular risk: A critical appraisal
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Letter by Awadhesh Kumar Singh Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
por: Lo, Chris Wai Hang, et al.
Publicado: (2021)

Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Singh, Awadhesh Kumar, et al.
Publicado: (2019)

Cardiovascular outcomes and safety with antidiabetic drugs
por: Aldossari, Khaled K.
Publicado: (2018)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
por: Fei, Yue, et al.
Publicado: (2019)

Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

At-admission hyperglycemia is consistently associated with poor prognosis and early intervention can improve outcomes in patients with COVID-19
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Letter to the editor in response to the article: “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (Kumar et al.)”
por: Kumar Singh, Awadhesh, et al.
Publicado: (2020)

Repurposing Antidiabetic Drugs for Cardiovascular Disease
por: Schubert, Mario, et al.
Publicado: (2020)

Efficacy and safety of teneligliptin
por: Singh, Awadhesh Kumar
Publicado: (2017)

Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

“Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Metformin in gestational diabetes: An emerging contender
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Editorial: Herd mentality, herds of migrants/people, and COVID-19 in India
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis
por: Lee, Gyeongsil, et al.
Publicado: (2017)

Meta‐analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes
por: Wolff, Georg, et al.
Publicado: (2022)

Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine
por: Zhang, Mei-Xian, et al.
Publicado: (2021)

Bariatric surgery and diabetes remission: Who would have thought it?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis
por: Cao, Hongwei, et al.
Publicado: (2022)

Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis
por: Cheung, BMY, et al.
Publicado: (2020)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Comments on: Rise of the phoenix: Mucormycosis in COVID-19 times
por: Singh, Awadhesh K, et al.
Publicado: (2021)

Letter in response to letter to the editor by Singh and Dhibar regarding the article “COVID-19: From bench to bedside” (Singh et al.)
por: Singh, Akriti, et al.
Publicado: (2020)

COVID-19: From bench to bed side
por: Singh, Akriti, et al.
Publicado: (2020)

An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19()
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
por: Fisman, Enrique Z., et al.
Publicado: (2015)

Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bpgvmlr3d2qi3be35udi7e3adt